Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic pooling
PubMed 32538188 · doi:10.1080/17512433.2020.1783247
What was done
This was a narrative review synthesizing available pharmacokinetic, pharmacodynamic, and clinical data on a progestin-only pill containing 4 mg drospirenone in a 24-day active plus 4-day hormone-free regimen. The review evaluated clinical effects including contraceptive efficacy, hemostatic impact, safety, tolerability, and bleeding patterns.
What was found
The abstract reports no numerical findings. It qualitatively reports that the drospirenone-only pill demonstrates a Pearl Index similar to common combined hormonal contraceptives, with higher rates of scheduled bleeding and substantially lower rates of unscheduled bleeding or spotting compared to traditional progestin-only pills, alongside lower rates of scheduled bleeding and higher rates of amenorrhea compared to estrogen-containing contraceptives.
Why it matters
This drospirenone regimen provides an estrogen-free oral contraceptive alternative designed to overcome the unpredictable bleeding patterns that commonly limit the clinical acceptability of traditional progestin-only pills.
Limits
The paper is a non-systematic narrative review, carrying inherent risk of study selection bias. The abstract provides no quantitative metrics, participant counts, statistical confidence intervals, or specific safety and adverse event rates.
Cited by
- supports Slynd is a progestin-only birth control pill that is anti-androgenic.